Results 31 to 40 of about 371,150 (199)

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Suppression of NF-κB Activity: A Viral Immune Evasion Mechanism

Viruses, 2018
Nuclear factor-κB (NF-κB) is an important transcription factor that induces the expression of antiviral genes and viral genes. NF-κB activation needs the activation of NF-κB upstream molecules, which include receptors, adaptor proteins, NF-κB (IκB ...
Liyao Deng, Qiurui Zeng, Mingshu Wang, Anchun Cheng, Renyong Jia, Shun Chen, Dekang Zhu, Mafeng Liu, Qiao Yang, Ying Wu, Xinxin Zhao, Shaqiu Zhang, Yunya Liu, Yanling Yu, Ling Zhang, Xiaoyue Chen   +15 more
doaj   +1 more source

Translating whole‐genome doubling into precision medicine in cancer

Molecular Oncology, EarlyView.
Whole‐genome doubling creates a WGD‐positive tumor state characterized by persistent chromosomal instability, karyotypic diversification, and cellular stress. These same biological pressures drive aggressive tumor evolution while exposing therapeutic vulnerabilities, providing a rationale for WGD‐informed precision medicine. Whole‐genome doubling (WGD)
Sejung Lee, Junghyeok Lim, Jinhyuk Bhin
wiley   +1 more source

The NF-κB Genomic Landscape in Lymphoblastoid B Cells

Cell Reports, 2014
The nuclear factor κB (NF-κΒ) subunits RelA, RelB, cRel, p50, and p52 are each critical for B cell development and function. To systematically characterize their responses to canonical and noncanonical NF-κB pathway activity, we performed chromatin ...
Bo Zhao, Luis A. Barrera, Ina Ersing, Bradford Willox, Stefanie C.S. Schmidt, Hannah Greenfeld, Hufeng Zhou, Sarah B. Mollo, Tommy T. Shi, Kaoru Takasaki, Sizun Jiang, Ellen Cahir-McFarland, Manolis Kellis, Martha L. Bulyk, Elliott Kieff, Benjamin E. Gewurz   +15 more
doaj   +1 more source

In Vivo Zonal Variation and Liver Cell-Type Specific NF-κB Localization after Chronic Adaptation to Ethanol and following Partial Hepatectomy. [PDF]

PLoS ONE, 2015
NF-κB is a major inflammatory response mediator in the liver, playing a key role in the pathogenesis of alcoholic liver injury. We investigated zonal as well as liver cell type-specific distribution of NF-κB activation across the liver acinus following ...
Harshavardhan Nilakantan, Lakshmi Kuttippurathu, Austin Parrish, Jan B Hoek, Rajanikanth Vadigepalli   +4 more
doaj   +1 more source

How to Inhibit Nuclear Factor-Kappa B Signaling: Lessons from Poxviruses

Pathogens, 2022
The Nuclear Factor-kappa B (NF-κB) family of transcription factors regulates key host inflammatory and antiviral gene expression programs, and thus, is often activated during viral infection through the action of pattern-recognition receptors and ...
Joshua B. Reus, Emily A. Rex, Don B. Gammon   +2 more
doaj   +1 more source

Targeting transcription factors associated with hemoglobinopathies: Lessons from successful interventions and implications for cancer

Molecular Oncology, EarlyView.
This review summarizes the transcription factors, repressive chromatin‐modifying complexes, and epigenetic mechanisms that control fetal hemoglobin repression. Notably, many regulators of γ‐globin silencing also function in transcriptional and epigenetic networks that drive cancer, highlighting opportunities to translate advances in hemoglobinopathy ...
Meigen Yu, Puspa Das, Xing Zhang, Xiaodong Cheng   +3 more
wiley   +1 more source

Nucleo-cytoplasmic trafficking of TRIM8, a novel oncogene, is involved in positive regulation of TNF induced NF-κB pathway. [PDF]

PLoS ONE, 2012
TNF induced nuclear factor kappa B (NF-κB) is one of the central signaling pathways that plays a critical role in carcinogenesis and inflammatory diseases.
Dhanendra Tomar, Lakshmi Sripada, Paresh Prajapati, Rochika Singh, Arun Kumar Singh, Rajesh Singh   +5 more
doaj   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

Comparison of activities of transcription factor NF-κB from two jellyfish models

Comparative Immunology Reports
Herein, transcription factor Nuclear Factor-kappaB (NF-κB) is characterized as the downstream effector of putative innate immune signaling pathways from two model jellyfish, Aurelia aurita (Aa) and Clytia hemisphaerica (Ch). Both jellyfish NF-κB proteins
Leah M. Williams, Wei Wang, Alexandra V. Grigoryeva, Alejandra Navarro-Rosado, Jada A. Peart, Angela Calderon, Catherine L. Gill, Susan Black, Kristina M. Alsante, Aidan T. Lackstrom, Molecular Biology Laboratory, Brandon Weissbourd, Mengrui Wang, Christopher J. DiRusso, Lianne B. Cohen, Zeba Wunderlich, Brian P. Grone, Thomas D. Gilmore   +17 more
doaj   +1 more source